Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Gut Pathogens
Published in: Gut Pathogens 1/2023

Open Access 01-12-2023 | Candida Albicans | Review

The interactions of Candida albicans with gut bacteria: a new strategy to prevent and treat invasive intestinal candidiasis

Authors: Fei Wang, Zetian Wang, Jianguo Tang

Published in: Gut Pathogens | Issue 1/2023

Login to get access

Abstract

Background

The gut microbiota plays an important role in human health, as it can affect host immunity and susceptibility to infectious diseases. Invasive intestinal candidiasis is strongly associated with gut microbiota homeostasis. However, the nature of the interaction between Candida albicans and gut bacteria remains unclear.

Objective

This review aimed to determine the nature of interaction and the effects of gut bacteria on C. albicans so as to comprehend an approach to reducing intestinal invasive infection by C. albicans.

Methods

This review examined 11 common gut bacteria’s interactions with C. albicans, including Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Enterococcus faecalis, Staphylococcus aureus, Salmonella spp., Helicobacter pylori, Lactobacillus spp., Bacteroides spp., Clostridium difficile, and Streptococcus spp.

Results

Most of the studied bacteria demonstrated both synergistic and antagonistic effects with C. albicans, and just a few bacteria such as P. aeruginosa, Salmonella spp., and Lactobacillus spp. demonstrated only antagonism against C. albicans.

Conclusions

Based on the nature of interactions reported so far by the literature between gut bacteria and C. albicans, it is expected to provide new ideas for the prevention and treatment of invasive intestinal candidiasis.
Literature
1.
Jenks JD, Cornely OA, Chen SC, Thompson GR 3rd, Hoenigl M. Breakthrough invasive fungal infections: who is at risk? Mycoses. 2020;63(10):1021–32.
2.
Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.PubMedCrossRef
3.
Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive candidiasis. Semin Respir Crit Care Med. 2020;41(1):3–12.PubMedCrossRef
4.
Tso GHW, Reales-Calderon JA, Pavelka N. The elusive Anti-Candida Vaccine: Lessons from the Past and Opportunities for the future. Front Immunol. 2018;9:897.PubMedPubMedCentralCrossRef
5.
Zhong L, Zhang S, Tang K, Zhou F, Zheng C, Zhang K, et al. Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections. BMC Infect Dis. 2020;20(1):810.PubMedPubMedCentralCrossRef
6.
Fusco A, Savio V, Donniacuo M, Perfetto B, Donnarumma G. Antimicrobial peptides human Beta-Defensin-2 and – 3 protect the Gut during Candida albicans Infections enhancing the Intestinal Barrier Integrity: in Vitro Study. Front Cell Infect Microbiol. 2021;11:666900.PubMedPubMedCentralCrossRef
7.
Desai JV, Lionakis MS. Setting up home: fungal rules of Commensalism in the mammalian gut. Cell Host Microbe. 2019;25(3):347–9.PubMedCrossRef
8.
Noble SM, Gianetti BA, Witchley JN. Candida albicans cell-type switching and functional plasticity in the mammalian host. Nat Rev Microbiol. 2017;15(2):96–108.PubMedCrossRef
9.
Tso GHW, Reales-Calderon JA, Tan ASM, Sem X, Le GTT, Tan TG, et al. Experimental evolution of a fungal pathogen into a gut symbiont. Science. 2018;362(6414):589–95.PubMedCrossRef
10.
Witchley JN, Penumetcha P, Abon NV, Woolford CA, Mitchell AP, Noble SM. Candida albicans morphogenesis Programs Control the balance between gut commensalism and invasive infection. Cell Host Microbe. 2019;25(3):432–43e6.PubMedPubMedCentralCrossRef
11.
Desai PR, van Wijlick L, Kurtz D, Juchimiuk M, Ernst JF. Hypoxia and temperature regulated morphogenesis in Candida albicans. PLoS Genet. 2015;11(8):e1005447.PubMedPubMedCentralCrossRef
12.
Pierce JV, Kumamoto CA. Variation in Candida albicans EFG1 expression enables host-dependent changes in colonizing fungal populations. mBio. 2012;3(4):e00117–12.PubMedPubMedCentralCrossRef
13.
Pande K, Chen C, Noble SM. Passage through the mammalian gut triggers a phenotypic switch that promotes Candida albicans commensalism. Nat Genet. 2013;45(9):1088–91.PubMedPubMedCentralCrossRef
14.
Prieto D, Román E, Alonso-Monge R, Pla J. Overexpression of the Transcriptional Regulator WOR1 increases susceptibility to bile salts and adhesion to the mouse gut mucosa in Candida albicans. Front Cell Infect Microbiol. 2017;7:389.PubMedPubMedCentralCrossRef
15.
Avican K, Fahlgren A, Huss M, Heroven AK, Beckstette M, Dersch P, et al. Reprogramming of Yersinia from virulent to persistent mode revealed by complex in vivo RNA-seq analysis. PLoS Pathog. 2015;11(1):e1004600.PubMedPubMedCentralCrossRef
16.
Barelle CJ, Priest CL, Maccallum DM, Gow NA, Odds FC, Brown AJ. Niche-specific regulation of central metabolic pathways in a fungal pathogen. Cell Microbiol. 2006;8(6):961–71.PubMedPubMedCentralCrossRef
17.
Hube B. From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr Opin Microbiol. 2004;7(4):336–41.PubMedCrossRef
18.
Kröger C, Colgan A, Srikumar S, Händler K, Sivasankaran SK, Hammarlöf DL, et al. An infection-relevant transcriptomic compendium for Salmonella enterica Serovar Typhimurium. Cell Host Microbe. 2013;14(6):683–95.PubMedCrossRef
19.
Miramón P, Dunker C, Windecker H, Bohovych IM, Brown AJ, Kurzai O, et al. Cellular responses of Candida albicans to phagocytosis and the extracellular activities of neutrophils are critical to counteract carbohydrate starvation, oxidative and nitrosative stress. PLoS ONE. 2012;7(12):e52850.PubMedPubMedCentralCrossRef
20.
Martínez P, Ljungdahl PO. An ER packaging chaperone determines the amino acid uptake capacity and virulence of Candida albicans. Mol Microbiol. 2004;51(2):371–84.PubMedCrossRef
21.
Martínez P, Ljungdahl PO. Divergence of Stp1 and Stp2 transcription factors in Candida albicans places virulence factors required for proper nutrient acquisition under amino acid control. Mol Cell Biol. 2005;25(21):9435–46.PubMedPubMedCentralCrossRef
22.
23.
Vylkova S, Carman AJ, Danhof HA, Collette JR, Zhou H, Lorenz MC. The fungal pathogen Candida albicans autoinduces hyphal morphogenesis by raising extracellular pH. mBio. 2011;2(3):e00055–11.PubMedPubMedCentralCrossRef
24.
Kastora SL, Herrero-de-Dios C, Avelar GM, Munro CA, Brown AJP. Sfp1 and Rtg3 reciprocally modulate carbon source-conditional stress adaptation in the pathogenic yeast Candida albicans. Mol Microbiol. 2017;105(4):620–36.PubMedPubMedCentralCrossRef
25.
Alonso-Roman R, Last A, Mirhakkak MH, Sprague JL, Möller L, Großmann P, et al. Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat Commun. 2022;13(1):3192.PubMedPubMedCentralCrossRef
26.
Andes D, Lepak A, Pitula A, Marchillo K, Clark J. A simple approach for estimating gene expression in Candida albicans directly from a systemic infection site. J Infect Dis. 2005;192(5):893–900.PubMedCrossRef
27.
Childers DS, Raziunaite I, Mol Avelar G, Mackie J, Budge S, Stead D, et al. The rewiring of ubiquitination targets in a pathogenic yeast promotes metabolic flexibility, host colonization and virulence. PLoS Pathog. 2016;12(4):e1005566.PubMedPubMedCentralCrossRef
28.
Fradin C, De Groot P, MacCallum D, Schaller M, Klis F, Odds FC, et al. Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood. Mol Microbiol. 2005;56(2):397–415.PubMedCrossRef
29.
Rosenbach A, Dignard D, Pierce JV, Whiteway M, Kumamoto CA. Adaptations of Candida albicans for growth in the mammalian intestinal tract. Eukaryot Cell. 2010;9(7):1075–86.PubMedPubMedCentralCrossRef
30.
Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 2008;4(4):e1000040.PubMedPubMedCentralCrossRef
31.
Heymann P, Gerads M, Schaller M, Dromer F, Winkelmann G, Ernst JF. The siderophore iron transporter of Candida albicans (Sit1p/Arn1p) mediates uptake of ferrichrome-type siderophores and is required for epithelial invasion. Infect Immun. 2002;70(9):5246–55.PubMedPubMedCentralCrossRef
32.
Lesuisse E, Knight SA, Camadro JM, Dancis A. Siderophore uptake by Candida albicans: effect of serum treatment and comparison with Saccharomyces cerevisiae. Yeast. 2002;19(4):329–40.PubMedCrossRef
33.
Moors MA, Stull TL, Blank KJ, Buckley HR, Mosser DM. A role for complement receptor-like molecules in iron acquisition by Candida albicans. J Exp Med. 1992;175(6):1643–51.PubMedCrossRef
34.
Ramanan N, Wang Y. A high-affinity iron permease essential for Candida albicans virulence. Science. 2000;288(5468):1062–4.PubMedCrossRef
35.
Chen C, Pande K, French SD, Tuch BB, Noble SM. An iron homeostasis regulatory circuit with reciprocal roles in Candida albicans commensalism and pathogenesis. Cell Host Microbe. 2011;10(2):118–35.PubMedPubMedCentralCrossRef
36.
Mamouei Z, Zeng G, Wang YM, Wang Y. Candida albicans possess a highly versatile and dynamic high-affinity iron transport system important for its commensal-pathogenic lifestyle. Mol Microbiol. 2017;106(6):986–98.PubMedCrossRef
37.
Eck R, Hundt S, Härtl A, Roemer E, Künkel W. A multicopper oxidase gene from Candida albicans: cloning, characterization and disruption. Microbiol (Reading). 1999;145(Pt 9):2415–22.CrossRef
38.
Knight SAB, Lesuisse E, Stearman R, Klausner RD, Dancis A. Reductive iron uptake by Candida albicans: role of copper, iron and the TUP1 regulator. Microbiol (Reading). 2002;148(Pt 1):29–40.CrossRef
39.
Ziegler L, Terzulli A, Gaur R, McCarthy R, Kosman DJ. Functional characterization of the ferroxidase, permease high-affinity iron transport complex from Candida albicans. Mol Microbiol. 2011;81(2):473–85.PubMedPubMedCentralCrossRef
40.
Weissman Z, Shemer R, Kornitzer D. Deletion of the copper transporter CaCCC2 reveals two distinct pathways for iron acquisition in Candida albicans. Mol Microbiol. 2002;44(6):1551–60.PubMedCrossRef
41.
Marvin ME, Mason RP, Cashmore AM. The CaCTR1 gene is required for high-affinity iron uptake and is transcriptionally controlled by a copper-sensing transactivator encoded by CaMAC1. Microbiol (Reading). 2004;150(Pt 7):2197–208.CrossRef
42.
Marvin ME, Williams PH, Cashmore AM. The Candida albicans CTR1 gene encodes a functional copper transporter. Microbiol (Reading). 2003;149(Pt 6):1461–74.CrossRef
43.
Riggle PJ, Kumamoto CA. Role of a Candida albicans P1-type ATPase in resistance to copper and silver ion toxicity. J Bacteriol. 2000;182(17):4899–905.PubMedPubMedCentralCrossRef
44.
Weissman Z, Berdicevsky I, Cavari BZ, Kornitzer D. The high copper tolerance of Candida albicans is mediated by a P-type ATPase. Proc Natl Acad Sci U S A. 2000;97(7):3520–5.PubMedPubMedCentralCrossRef
45.
46.
Citiulo F, Jacobsen ID, Miramón P, Schild L, Brunke S, Zipfel P, et al. Candida albicans scavenges host zinc via Pra1 during endothelial invasion. PLoS Pathog. 2012;8(6):e1002777.PubMedPubMedCentralCrossRef
47.
Kim MJ, Kil M, Jung JH, Kim J. Roles of zinc-responsive transcription factor Csr1 in filamentous growth of the pathogenic yeast Candida albicans. J Microbiol Biotechnol. 2008;18(2):242–7.PubMedCrossRef
48.
Kumar R, Breindel C, Saraswat D, Cullen PJ, Edgerton M. Candida albicans Sap6 amyloid regions function in cellular aggregation and zinc binding, and contribute to zinc acquisition. Sci Rep. 2017;7(1):2908.PubMedPubMedCentralCrossRef
49.
Crawford AC, Lehtovirta-Morley LE, Alamir O, Niemiec MJ, Alawfi B, Alsarraf M, et al. Biphasic zinc compartmentalisation in a human fungal pathogen. PLoS Pathog. 2018;14(5):e1007013.PubMedPubMedCentralCrossRef
50.
de Dios CH, Román E, Monge RA, Pla J. The role of MAPK signal transduction pathways in the response to oxidative stress in the fungal pathogen Candida albicans: implications in virulence. Curr Protein Pept Sci. 2010;11(8):693–703.PubMedCrossRef
51.
Monge RA, Román E, Nombela C, Pla J. The MAP kinase signal transduction network in Candida albicans. Microbiol (Reading). 2006;152(Pt 4):905–12.CrossRef
52.
Alonso-Monge R, Navarro-García F, Román E, Negredo AI, Eisman B, Nombela C, et al. The Hog1 mitogen-activated protein kinase is essential in the oxidative stress response and chlamydospore formation in Candida albicans. Eukaryot Cell. 2003;2(2):351–61.PubMedPubMedCentralCrossRef
53.
San José C, Monge RA, Pérez-Díaz R, Pla J, Nombela C. The mitogen-activated protein kinase homolog HOG1 gene controls glycerol accumulation in the pathogenic fungus Candida albicans. J Bacteriol. 1996;178(19):5850–2.PubMedPubMedCentralCrossRef
54.
Smith DA, Nicholls S, Morgan BA, Brown AJ, Quinn J. A conserved stress-activated protein kinase regulates a core stress response in the human pathogen Candida albicans. Mol Biol Cell. 2004;15(9):4179–90.PubMedPubMedCentralCrossRef
55.
Alarco AM, Raymond M. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J Bacteriol. 1999;181(3):700–8.PubMedPubMedCentralCrossRef
56.
Kos I, Patterson MJ, Znaidi S, Kaloriti D, da Silva Dantas A, Herrero-de-Dios CM, et al. Mechanisms underlying the delayed activation of the Cap1 transcription factor in Candida albicans following combinatorial oxidative and cationic stress important for phagocytic potency. mBio. 2016;7(2):e00331.PubMedPubMedCentralCrossRef
57.
Znaidi S, Barker KS, Weber S, Alarco AM, Liu TT, Boucher G, et al. Identification of the Candida albicans Cap1p regulon. Eukaryot Cell. 2009;8(6):806–20.PubMedPubMedCentralCrossRef
58.
Eisman B, Alonso-Monge R, Román E, Arana D, Nombela C, Pla J. The Cek1 and Hog1 mitogen-activated protein kinases play complementary roles in cell wall biogenesis and chlamydospore formation in the fungal pathogen Candida albicans. Eukaryot Cell. 2006;5(2):347–58.PubMedPubMedCentralCrossRef
59.
Navarro-García F, Sánchez M, Pla J, Nombela C. Functional characterization of the MKC1 gene of Candida albicans, which encodes a mitogen-activated protein kinase homolog related to cell integrity. Mol Cell Biol. 1995;15(4):2197–206.PubMedPubMedCentralCrossRef
60.
Chiranand W, McLeod I, Zhou H, Lynn JJ, Vega LA, Myers H, et al. CTA4 transcription factor mediates induction of nitrosative stress response in Candida albicans. Eukaryot Cell. 2008;7(2):268–78.PubMedCrossRef
61.
Hromatka BS, Noble SM, Johnson AD. Transcriptional response of Candida albicans to nitric oxide and the role of the YHB1 gene in nitrosative stress and virulence. Mol Biol Cell. 2005;16(10):4814–26.PubMedPubMedCentralCrossRef
62.
Nicholls S, Leach MD, Priest CL, Brown AJ. Role of the heat shock transcription factor, Hsf1, in a major fungal pathogen that is obligately associated with warm-blooded animals. Mol Microbiol. 2009;74(4):844–61.PubMedPubMedCentralCrossRef
63.
Tan TG, Lim YS, Tan A, Leong R, Pavelka N. Fungal symbionts produce prostaglandin E(2) to promote their intestinal colonization. Front Cell Infect Microbiol. 2019;9:359.PubMedPubMedCentralCrossRef
64.
Brown AJ, Brown GD, Netea MG, Gow NA. Metabolism impacts upon Candida immunogenicity and pathogenicity at multiple levels. Trends Microbiol. 2014;22(11):614–22.PubMedPubMedCentralCrossRef
65.
Leimbach A, Hacker J, Dobrindt U. E. coli as an all-rounder: the thin line between commensalism and pathogenicity. Curr Top Microbiol Immunol. 2013;358:3–32.PubMed
66.
Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8(3):207–17.PubMedCrossRef
67.
Farrokhi Y, Al-Shibli B, Al-Hameedawi DF, Neshati Z, Makhdoumi A. Escherichia coli enhances the virulence factors of Candida albicans, the cause of vulvovaginal candidiasis, in a dual bacterial/fungal biofilm. Res Microbiol. 2021;172(4–5):103849.PubMedCrossRef
68.
Klaerner HG, Uknis ME, Acton RD, Dahlberg PS, Carlone-Jambor C, Dunn DL. Candida albicans and Escherichia coli are synergistic pathogens during experimental microbial peritonitis. J Surg Res. 1997;70(2):161–5.PubMedCrossRef
69.
Bandara H, Yau JYY, Watt RM, Jin LJ, Samaranayake LP. Escherichia coli and its lipopolysaccharide modulate in vitro Candida biofilm formation. J Med Microbiol. 2009;58(Pt 12):1623–31.PubMedCrossRef
70.
71.
Bandara HM, Cheung BP, Watt RM, Jin LJ, Samaranayake LP. Secretory products of Escherichia coli biofilm modulate Candida biofilm formation and hyphal development. J Investig Clin Dent. 2013;4(3):186–99.PubMedCrossRef
72.
Cabral DJ, Penumutchu S, Norris C, Morones-Ramirez JR, Belenky P. Microbial competition between Escherichia coli and Candida albicans reveals a soluble fungicidal factor. Microb Cell. 2018;5(5):249–55.PubMedPubMedCentralCrossRef
73.
Mielko KA, Jabłoński SJ, Milczewska J, Sands D, Łukaszewicz M, Młynarz P. Metabolomic studies of Pseudomonas aeruginosa. World J Microbiol Biotechnol. 2019;35(11):178.PubMedPubMedCentralCrossRef
74.
Kasetty S, Mould DL, Hogan DA, Nadell CD. Both Pseudomonas aeruginosa and Candida albicans Accumulate Greater Biomass in Dual-Species Biofilms under Flow. mSphere. 2021;6(3):e0041621.PubMedCrossRef
75.
Hamet M, Pavon A, Dalle F, Pechinot A, Prin S, Quenot JP, et al. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia. Intensive Care Med. 2012;38(8):1272–9.PubMedCrossRef
76.
Navarro J, Rainisio M, Harms HK, Hodson ME, Koch C, Mastella G, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European epidemiologic Registry of cystic fibrosis. Eur Respir J. 2001;18(2):298–305.PubMedCrossRef
77.
Azoulay E, Timsit JF, Tafflet M, de Lassence A, Darmon M, Zahar JR, et al. Candida colonization of the respiratory tract and subsequent pseudomonas ventilator-associated pneumonia. Chest. 2006;129(1):110–7.PubMedCrossRef
78.
Roux D, Gaudry S, Dreyfuss D, El-Benna J, de Prost N, Denamur E, et al. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit Care Med. 2009;37(3):1062–7.PubMedCrossRef
79.
Nseir S, Jozefowicz E, Cavestri B, Sendid B, Di Pompeo C, Dewavrin F, et al. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive Care Med. 2007;33(1):137–42.PubMedCrossRef
80.
Hiengrach P, Panpetch W, Worasilchai N, Chindamporn A, Tumwasorn S, Jaroonwitchawan T, et al. Administration of Candida Albicans to dextran sulfate solution treated mice causes intestinal dysbiosis, emergence and dissemination of Intestinal Pseudomonas Aeruginosa and Lethal Sepsis. Shock. 2020;53(2):189–98.PubMedCrossRef
81.
Keçeli Özcan S, Dündar D, Sönmez TG. [Anti-candidal activity of clinical Pseudomonas aeruginosa strains and in vitro inhibition of Candida biofilm formation]. Mikrobiyol Bul. 2012;46(1):39–46.PubMed
82.
Morales DK, Jacobs NJ, Rajamani S, Krishnamurthy M, Cubillos-Ruiz JR, Hogan DA. Antifungal mechanisms by which a novel Pseudomonas aeruginosa phenazine toxin kills Candida albicans in biofilms. Mol Microbiol. 2010;78(6):1379–92.PubMedCrossRef
83.
Morales DK, Grahl N, Okegbe C, Dietrich LE, Jacobs NJ, Hogan DA. Control of Candida albicans metabolism and biofilm formation by Pseudomonas aeruginosa phenazines. mBio. 2013;4(1):e00526–12.PubMedPubMedCentralCrossRef
84.
Hogan DA, Vik A, Kolter R. A Pseudomonas aeruginosa quorum-sensing molecule influences Candida albicans morphology. Mol Microbiol. 2004;54(5):1212–23.PubMedCrossRef
85.
Chen AI, Dolben EF, Okegbe C, Harty CE, Golub Y, Thao S, et al. Candida albicans ethanol stimulates Pseudomonas aeruginosa WspR-controlled biofilm formation as part of a cyclic relationship involving phenazines. PLoS Pathog. 2014;10(10):e1004480.PubMedPubMedCentralCrossRef
86.
Lopez-Medina E, Fan D, Coughlin LA, Ho EX, Lamont IL, Reimmann C, et al. Candida albicans inhibits Pseudomonas aeruginosa Virulence through suppression of pyochelin and pyoverdine biosynthesis. PLoS Pathog. 2015;11(8):e1005129.PubMedPubMedCentralCrossRef
87.
Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16(2):91–102.PubMedCrossRef
88.
Lee CR, Lee JH, Park M, Park KS, Bae IK, Kim YB, et al. Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and prospective treatment options. Front Cell Infect Microbiol. 2017;7:55.PubMedPubMedCentralCrossRef
89.
Richards AM, Abu Kwaik Y, Lamont RJ. Code blue: Acinetobacter baumannii, a nosocomial pathogen with a role in the oral cavity. Mol Oral Microbiol. 2015;30(1):2–15.PubMedCrossRef
90.
Ketter PM, Yu JJ, Guentzel MN, May HC, Gupta R, Eppinger M et al. Acinetobacter baumannii Gastrointestinal colonization is facilitated by secretory IgA which is reductively dissociated by bacterial thioredoxin A. mBio. 2018;9(4).
91.
Tan X, Zhu S, Yan D, Chen W, Chen R, Zou J, et al. Candida spp. airway colonization: a potential risk factor for Acinetobacter baumannii ventilator-associated pneumonia. Med Mycol. 2016;54(6):557–66.PubMedCrossRef
92.
Tan X, Chen R, Zhu S, Wang H, Yan D, Zhang X, et al. Candida albicans Airway colonization facilitates subsequent Acinetobacter baumannii Pneumonia in a rat model. Antimicrob Agents Chemother. 2016;60(6):3348–54.PubMedPubMedCentralCrossRef
93.
94.
Camarena L, Bruno V, Euskirchen G, Poggio S, Snyder M. Molecular mechanisms of ethanol-induced pathogenesis revealed by RNA-sequencing. PLoS Pathog. 2010;6(4):e1000834.PubMedPubMedCentralCrossRef
95.
Uppuluri P, Lin L, Alqarihi A, Luo G, Youssef EG, Alkhazraji S, et al. The Hyr1 protein from the fungus Candida albicans is a cross kingdom immunotherapeutic target for Acinetobacter bacterial infection. PLoS Pathog. 2018;14(5):e1007056.PubMedPubMedCentralCrossRef
96.
Kostoulias X, Murray GL, Cerqueira GM, Kong JB, Bantun F, Mylonakis E, et al. Impact of a Cross-Kingdom Signaling Molecule of Candida albicans on Acinetobacter baumannii Physiology. Antimicrob Agents Chemother. 2016;60(1):161–7.PubMedCrossRef
97.
Peleg AY, Tampakakis E, Fuchs BB, Eliopoulos GM, Moellering RC Jr, Mylonakis E. Prokaryote-eukaryote interactions identified by using Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2008;105(38):14585–90.PubMedPubMedCentralCrossRef
98.
Gaddy JA, Tomaras AP, Actis LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells. Infect Immun. 2009;77(8):3150–60.PubMedPubMedCentralCrossRef
99.
100.
Oh HK, Hwang YJ, Hong HW, Myung H. Comparison of Enterococcus faecalis Biofilm removal efficiency among bacteriophage PBEF129, its Endolysin, and Cefotaxime. Viruses. 2021;13(3).
101.
Reffuveille F, Leneveu C, Chevalier S, Auffray Y, Rincé A. Lipoproteins of Enterococcus faecalis: bioinformatic identification, expression analysis and relation to virulence. Microbiol (Reading). 2011;157(Pt 11):3001–13.CrossRef
102.
Ishijima SA, Hayama K, Ninomiya K, Iwasa M, Yamazaki M, Abe S. Protection of mice from oral candidiasis by heat-killed enterococcus faecalis, possibly through its direct binding to Candida albicans. Med Mycol J. 2014;55(1):E9–e19.PubMedCrossRef
103.
Cruz MR, Graham CE, Gagliano BC, Lorenz MC, Garsin DA. Enterococcus faecalis inhibits hyphal morphogenesis and virulence of Candida albicans. Infect Immun. 2013;81(1):189–200.PubMedPubMedCentralCrossRef
104.
Graham CE, Cruz MR, Garsin DA, Lorenz MC. Enterococcus faecalis bacteriocin EntV inhibits hyphal morphogenesis, biofilm formation, and virulence of Candida albicans. Proc Natl Acad Sci U S A. 2017;114(17):4507–12.PubMedPubMedCentralCrossRef
105.
106.
Du Q, Yuan S, Zhao S, Fu D, Chen Y, Zhou Y, et al. Coexistence of Candida albicans and Enterococcus faecalis increases biofilm virulence and periapical lesions in rats. Biofouling. 2021;37(9–10):964–74.PubMedCrossRef
107.
Gao Y, Jiang X, Lin D, Chen Y, Tong Z. The Starvation Resistance and Biofilm formation of Enterococcus faecalis in coexistence with Candida albicans, Streptococcus gordonii, Actinomyces viscosus, or Lactobacillus acidophilus. J Endod. 2016;42(8):1233–8.PubMedCrossRef
108.
Mason KL, Erb Downward JR, Falkowski NR, Young VB, Kao JY, Huffnagle GB. Interplay between the gastric bacterial microbiota and Candida albicans during postantibiotic recolonization and gastritis. Infect Immun. 2012;80(1):150–8.PubMedPubMedCentralCrossRef
109.
Mason KL, Erb Downward JR, Mason KD, Falkowski NR, Eaton KA, Kao JY, et al. Candida albicans and bacterial microbiota interactions in the cecum during recolonization following broad-spectrum antibiotic therapy. Infect Immun. 2012;80(10):3371–80.PubMedPubMedCentralCrossRef
110.
Kart D, Yabanoğlu Çiftçi S, Nemutlu E. Metabolomics-driven approaches on interactions between Enterococcus faecalis and Candida albicans Biofilms. Turk J Pharm Sci. 2021;18(5):557–64.PubMedPubMedCentralCrossRef
111.
Ahmad-Mansour N, Loubet P, Pouget C, Dunyach-Remy C, Sotto A, Lavigne JP et al. Staphylococcus aureus Toxins: an update on their pathogenic Properties and potential treatments. Toxins (Basel). 2021;13(10).
112.
Peters BM, Noverr MC. Candida albicans-Staphylococcus aureus polymicrobial peritonitis modulates host innate immunity. Infect Immun. 2013;81(6):2178–89.PubMedPubMedCentralCrossRef
113.
Scheres N, Krom BP. Staphylococcus-Candida Interaction Models: antibiotic resistance testing and host interactions. Methods Mol Biol. 2016;1356:153–61.PubMedCrossRef
114.
Todd OA, Fidel PL Jr, Harro JM, Hilliard JJ, Tkaczyk C, Sellman BR et al. Candida albicans augments Staphylococcus aureus Virulence by engaging the staphylococcal agr Quorum Sensing System. mBio. 2019;10(3).
115.
Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. Nonfilamentous C. albicans mutants are avirulent. Cell. 1997;90(5):939–49.PubMedCrossRef
116.
Nash EE, Peters BM, Fidel PL, Noverr MC. Morphology-independent virulence of Candida Species during Polymicrobial intra-abdominal infections with Staphylococcus aureus. Infect Immun. 2016;84(1):90–8.PubMedCrossRef
117.
118.
Nash EE, Peters BM, Palmer GE, Fidel PL, Noverr MC. Morphogenesis is not required for Candida albicans-Staphylococcus aureus intra-abdominal infection-mediated dissemination and lethal sepsis. Infect Immun. 2014;82(8):3426–35.PubMedPubMedCentralCrossRef
119.
Vila T, Kong EF, Montelongo-Jauregui D, Van Dijck P, Shetty AC, McCracken C, et al. Therapeutic implications of C. albicans-S. aureus mixed biofilm in a murine subcutaneous catheter model of polymicrobial infection. Virulence. 2021;12(1):835–51.PubMedPubMedCentralCrossRef
120.
Kong EF, Tsui C, Kucharíková S, Van Dijck P, Jabra-Rizk MA. Modulation of Staphylococcus aureus Response to Antimicrobials by the Candida albicans Quorum sensing Molecule Farnesol. Antimicrob Agents Chemother. 2017;61(12).
121.
Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P, Cassone A. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun. 1986;51(2):668–74.PubMedPubMedCentralCrossRef
122.
Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.PubMedPubMedCentralCrossRef
123.
Di Luzio NR, Williams DL. Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leukemic mice. Infect Immun. 1978;20(3):804–10.PubMedPubMedCentralCrossRef
124.
Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20(6):375–88.PubMedPubMedCentralCrossRef
125.
Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe. 2011;9(5):355–61.PubMedCrossRef
126.
Quintin J, Saeed S, Martens JHA, Giamarellos-Bourboulis EJ, Ifrim DC, Logie C, et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe. 2012;12(2):223–32.PubMedCrossRef
127.
128.
Petersen E, Miller SI. The cellular microbiology of Salmonellae interactions with macrophages. Cell Microbiol. 2019;21(11):e13116.PubMedCrossRef
129.
Tampakakis E, Peleg AY, Mylonakis E. Interaction of Candida albicans with an intestinal pathogen, Salmonella enterica serovar typhimurium. Eukaryot Cell. 2009;8(5):732–7.PubMedPubMedCentralCrossRef
130.
Ly KT, Casanova JE. Mechanisms of Salmonella entry into host cells. Cell Microbiol. 2007;9(9):2103–11.PubMedCrossRef
131.
McGhie EJ, Brawn LC, Hume PJ, Humphreys D, Koronakis V. Salmonella takes control: effector-driven manipulation of the host. Curr Opin Microbiol. 2009;12(1):117–24.PubMedPubMedCentralCrossRef
132.
Zhou D, Galán J. Salmonella entry into host cells: the work in concert of type III secreted effector proteins. Microbes Infect. 2001;3(14–15):1293–8.PubMedCrossRef
133.
134.
Winarsih S, Kosasih T, Putera MA, Rahmadhiani N, Poernomo EL, Runtuk KS, et al. β-Glucan of Candida albicans Cell Wall Extract inhibits Salmonella Typhimurium colonization by potentiating Cellular immunity (CD8 + and CD4 + T cells). Rev Soc Bras Med Trop. 2019;52:e20180254.PubMedCrossRef
135.
136.
137.
Chu YT, Wang YH, Wu JJ, Lei HY. Invasion and multiplication of Helicobacter pylori in gastric epithelial cells and implications for antibiotic resistance. Infect Immun. 2010;78(10):4157–65.PubMedPubMedCentralCrossRef
138.
139.
Petersen AM, Krogfelt KA. Helicobacter pylori: an invading microorganism? A review. FEMS Immunol Med Microbiol. 2003;36(3):117–26.PubMedCrossRef
140.
141.
Wang YH, Wu JJ, Lei HY. The autophagic induction in Helicobacter pylori-infected macrophage. Exp Biol Med (Maywood). 2009;234(2):171–80.PubMedCrossRef
142.
Siavoshi F, Salmanian AH, Akbari F, Malekzadeh R, Massarrat S. Detection of Helicobacter pylori-specific genes in the oral yeast. Helicobacter. 2005;10(4):318–22.PubMedCrossRef
143.
Gehrig H, Schüssler A, Kluge M. Geosiphon pyriforme, a fungus forming endocytobiosis with Nostoc (cyanobacteria), is an ancestral member of the Glomales: evidence by SSU rRNA analysis. J Mol Evol. 1996;43(1):71–81.PubMedCrossRef
144.
Salmanian AH, Siavoshi F, Akbari F, Afshari A, Malekzadeh R. Yeast of the oral cavity is the reservoir of Heliobacter pylori. J Oral Pathol Med. 2008;37(6):324–8.PubMedCrossRef
145.
Saniee P, Siavoshi F, Nikbakht Broujeni G, Khormali M, Sarrafnejad A, Malekzadeh R. Localization of H.pylori within the vacuole of Candida yeast by direct immunofluorescence technique. Arch Iran Med. 2013;16(12):705–10.PubMed
146.
Saniee P, Siavoshi F, Nikbakht Broujeni G, Khormali M, Sarrafnejad A, Malekzadeh R. Immunodetection of Helicobacter pylori-specific proteins in oral and gastric Candida yeasts. Arch Iran Med. 2013;16(11):624–30.PubMed
147.
148.
Sánchez-Alonzo K, Parra-Sepúlveda C, Vega S, Bernasconi H, Campos VL, Smith CT et al. In Vitro Incorporation of Helicobacter pylori into Candida albicans caused by acidic pH stress. Pathogens. 2020;9(6).
149.
Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT et al. Antibiotics as a stressing factor triggering the harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens. 2021;10(3).
150.
Massarrat S, Saniee P, Siavoshi F, Mokhtari R, Mansour-Ghanaei F, Khalili-Samani S. The Effect of Helicobacter pylori infection, aging, and consumption of Proton Pump inhibitor on fungal colonization in the stomach of dyspeptic patients. Front Microbiol. 2016;7:801.PubMedPubMedCentralCrossRef
151.
Heydari S, Siavoshi F, Jazayeri MH, Sarrafnejad A, Saniee P. Helicobacter pylori release from yeast as a vesicle-encased or free bacterium. Helicobacter. 2020;25(5):e12725.PubMedCrossRef
152.
Siavoshi F, Taghikhani A, Malekzadeh R, Sarrafnejad A, Kashanian M, Jamal AS, et al. The role of mother’s oral and vaginal yeasts in transmission of Helicobacter pylori to neonates. Arch Iran Med. 2013;16(5):288–94.PubMed
153.
Lee DG, Kim PI, Park Y, Jang SH, Park SC, Woo ER, et al. HP (2–20) derived from the amino terminal region of helicobacterpylori ribosomal protein L1 exerts its antifungal effects by damaging the plasma membranes of Candida albicans. J Pept Sci. 2002;8(8):453–60.PubMedCrossRef
154.
Lee DG, Park Y, Kim HN, Kim HK, Kim PI, Choi BH, et al. Antifungal mechanism of an antimicrobial peptide, HP (2–20), derived from N-terminus of Helicobacter pylori ribosomal protein L1 against Candida albicans. Biochem Biophys Res Commun. 2002;291(4):1006–13.PubMedCrossRef
155.
Lee DG, Park Y, Kim PI, Jeong HG, Woo ER, Hahm KS. Influence on the plasma membrane of Candida albicans by HP (2–9)-magainin 2 (1–12) hybrid peptide. Biochem Biophys Res Commun. 2002;297(4):885–9.PubMedCrossRef
156.
Park Y, Lee DG, Hahm KS. HP(2–9)-magainin 2(1–12), a synthetic hybrid peptide, exerts its antifungal effect on Candida albicans by damaging the plasma membrane. J Pept Sci. 2004;10(4):204–9.PubMedCrossRef
157.
Rossi F, Amadoro C, Colavita G. Members of the Lactobacillus Genus Complex (LGC) as opportunistic pathogens: a review. Microorganisms. 2019;7(5).
158.
Goldstein EJ, Tyrrell KL, Citron DM. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis. 2015;60(Suppl 2):98–107.CrossRef
159.
Graf K, Last A, Gratz R, Allert S, Linde S, Westermann M et al. Keeping Candida commensal: how lactobacilli antagonize pathogenicity of Candida albicans in an in vitro gut model. Dis Model Mech. 2019;12(9).
160.
Panpetch W, Hiengrach P, Nilgate S, Tumwasorn S, Somboonna N, Wilantho A, et al. Additional Candida albicans administration enhances the severity of dextran sulfate solution induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34. Gut Microbes. 2020;11(3):465–80.PubMedCrossRef
161.
Roy A, Chaudhuri J, Sarkar D, Ghosh P, Chakraborty S. Role of enteric supplementation of Probiotics on late-onset Sepsis by Candida species in Preterm Low Birth Weight Neonates: a Randomized, double blind, placebo-controlled trial. N Am J Med Sci. 2014;6(1):50–7.PubMedPubMedCentralCrossRef
162.
Boris S, Barbés C. Role played by lactobacilli in controlling the population of vaginal pathogens. Microbes Infect. 2000;2(5):543–6.PubMedCrossRef
163.
164.
Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22. Immunity. 2013;39(2):372–85.PubMedCrossRef
165.
Dube Y, Khan A, Marimani M, Ahmad A. Lactobacillus rhamnosus cell-free extract targets virulence and antifungal drug resistance in Candida albicans. Can J Microbiol. 2020;66(12):733–47.PubMedCrossRef
166.
Erb Downward JR, Falkowski NR, Mason KL, Muraglia R, Huffnagle GB. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. Sci Rep. 2013;3:2191.PubMedPubMedCentralCrossRef
167.
168.
García C, Tebbji F, Daigneault M, Liu NN, Köhler JR, Allen-Vercoe E et al. The human gut Microbial Metabolome modulates fungal growth via the TOR Signaling Pathway. mSphere. 2017;2(6).
169.
Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. Activation of HIF-1α and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med. 2015;21(7):808–14.PubMedPubMedCentralCrossRef
170.
López-García B, Lee PH, Yamasaki K, Gallo RL. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol. 2005;125(1):108–15.PubMedCrossRef
171.
172.
Peyssonnaux C, Datta V, Cramer T, Doedens A, Theodorakis EA, Gallo RL, et al. HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest. 2005;115(7):1806–15.PubMedPubMedCentralCrossRef
173.
Tsai PW, Yang CY, Chang HT, Lan CY. Human antimicrobial peptide LL-37 inhibits adhesion of Candida albicans by interacting with yeast cell-wall carbohydrates. PLoS ONE. 2011;6(3):e17755.PubMedPubMedCentralCrossRef
174.
Eckstein MT, Moreno-Velásquez SD, Pérez JC. Gut Bacteria shape intestinal Microhabitats occupied by the Fungus Candida albicans. Curr Biol. 2020;30(23):4799–807e4.PubMedCrossRef
175.
Fox EP, Cowley ES, Nobile CJ, Hartooni N, Newman DK, Johnson AD. Anaerobic bacteria grow within Candida albicans biofilms and induce biofilm formation in suspension cultures. Curr Biol. 2014;24(20):2411–6.PubMedPubMedCentralCrossRef
176.
Valentine M, Benadé E, Mouton M, Khan W, Botha A. Binary interactions between the yeast Candida albicans and two gut-associated Bacteroides species. Microb Pathog. 2019;135:103619.PubMedCrossRef
177.
Anjuwon-Foster BR, Tamayo R. Phase variation of Clostridium difficile virulence factors. Gut Microbes. 2018;9(1):76–83.PubMedCrossRef
178.
179.
Zuo T, Wong SH, Cheung CP, Lam K, Lui R, Cheung K, et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat Commun. 2018;9(1):3663.PubMedPubMedCentralCrossRef
180.
van Leeuwen PT, van der Peet JM, Bikker FJ, Hoogenkamp MA, Oliveira Paiva AM, Kostidis S et al. Interspecies interactions between Clostridium difficile and Candida albicans. mSphere. 2016;1(6).
181.
Raponi G, Visconti V, Brunetti G, Ghezzi MC. Clostridium difficile infection and Candida colonization of the gut: is there a correlation? Clin Infect Dis. 2014;59(11):1648–9.PubMedCrossRef
182.
Thangamani S, Monasky R, Lee JK, Antharam V, HogenEsch H, Hazbun TR et al. Bile acid regulates the colonization and dissemination of Candida albicans from the gastrointestinal tract by Controlling host Defense System and Microbiota. J Fungi (Basel). 2021;7(12).
183.
Passmore IJ, Letertre MPM, Preston MD, Bianconi I, Harrison MA, Nasher F, et al. Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria. PLoS Pathog. 2018;14(9):e1007191.PubMedPubMedCentralCrossRef
184.
Andam CP, Hanage WP. Mechanisms of genome evolution of Streptococcus. Infect Genet Evol. 2015;33:334–42.PubMedCrossRef
185.
Jenkinson HF, Lala HC, Shepherd MG. Coaggregation of Streptococcus sanguis and other streptococci with Candida albicans. Infect Immun. 1990;58(5):1429–36.PubMedPubMedCentralCrossRef
186.
Ellepola K, Truong T, Liu Y, Lin Q, Lim TK, Lee YM et al. Multi-omics analyses reveal synergistic Carbohydrate Metabolism in Streptococcus mutans-Candida albicans mixed-species biofilms. Infect Immun. 2019;87(10).
187.
Falsetta ML, Klein MI, Colonne PM, Scott-Anne K, Gregoire S, Pai CH, et al. Symbiotic relationship between Streptococcus mutans and Candida albicans synergizes virulence of plaque biofilms in vivo. Infect Immun. 2014;82(5):1968–81.PubMedPubMedCentralCrossRef
188.
Hwang G, Liu Y, Kim D, Li Y, Krysan DJ, Koo H. Candida albicans mannans mediate Streptococcus mutans exoenzyme GtfB binding to modulate cross-kingdom biofilm development in vivo. PLoS Pathog. 2017;13(6):e1006407.PubMedPubMedCentralCrossRef
189.
Hwang G, Marsh G, Gao L, Waugh R, Koo H. Binding Force Dynamics of Streptococcus mutans-glucosyltransferase B to Candida albicans. J Dent Res. 2015;94(9):1310–7.PubMedPubMedCentralCrossRef
190.
Koo H, Xiao J, Klein MI, Jeon JG. Exopolysaccharides produced by Streptococcus mutans glucosyltransferases modulate the establishment of microcolonies within multispecies biofilms. J Bacteriol. 2010;192(12):3024–32.PubMedPubMedCentralCrossRef
191.
Rainey K, Michalek SM, Wen ZT, Wu H. Glycosyltransferase-mediated Biofilm Matrix Dynamics and Virulence of Streptococcus mutans. Appl Environ Microbiol. 2019;85(5).
192.
Souza JGS, Bertolini M, Thompson A, Mansfield JM, Grassmann AA, Maas K, et al. Role of glucosyltransferase R in biofilm interactions between Streptococcus oralis and Candida albicans. Isme j. 2020;14(5):1207–22.PubMedPubMedCentralCrossRef
193.
Yang C, Scoffield J, Wu R, Deivanayagam C, Zou J, Wu H. Antigen I/II mediates interactions between Streptococcus mutans and Candida albicans. Mol Oral Microbiol. 2018;33(4):283–91.PubMedPubMedCentralCrossRef
194.
Khoury ZH, Vila T, Puthran TR, Sultan AS, Montelongo-Jauregui D, Melo MAS, et al. The role of Candida albicans Secreted Polysaccharides in augmenting Streptococcus mutans adherence and mixed biofilm formation: in vitro and in vivo studies. Front Microbiol. 2020;11:307.PubMedPubMedCentralCrossRef
195.
Dutton LC, Paszkiewicz KH, Silverman RJ, Splatt PR, Shaw S, Nobbs AH, et al. Transcriptional landscape of trans-kingdom communication between Candida albicans and Streptococcus gordonii. Mol Oral Microbiol. 2016;31(2):136–61.PubMedCrossRef
196.
Montelongo-Jauregui D, Saville SP, Lopez-Ribot JL. Contributions of Candida albicans Dimorphism, Adhesive interactions, and Extracellular Matrix to the formation of dual-species biofilms with Streptococcus gordonii. mBio. 2019;10(3).
197.
Montelongo-Jauregui D, Srinivasan A, Ramasubramanian AK, Lopez-Ribot JL. An in Vitro Model for oral mixed biofilms of Candida albicans and Streptococcus gordonii in Synthetic Saliva. Front Microbiol. 2016;7:686.PubMedPubMedCentralCrossRef
198.
Montelongo-Jauregui D, Srinivasan A, Ramasubramanian AK, Lopez-Ribot JL. An in Vitro Model for Candida albicans-Streptococcus gordonii Biofilms on Titanium Surfaces. J Fungi (Basel). 2018;4(2).
199.
Ricker A, Vickerman M, Dongari-Bagtzoglou A. Streptococcus gordonii glucosyltransferase promotes biofilm interactions with Candida albicans. J Oral Microbiol. 2014;6.
200.
Zhou Z, Ren B, Li J, Zhou X, Xu X, Zhou Y. The role of Glycoside Hydrolases in S. gordonii and C. albicans interactions. Appl Environ Microbiol. 2022;88(10):e0011622.PubMedCrossRef
201.
Jack AA, Daniels DE, Jepson MA, Vickerman MM, Lamont RJ, Jenkinson HF, et al. Streptococcus gordonii comCDE (competence) operon modulates biofilm formation with Candida albicans. Microbiol (Reading). 2015;161(Pt 2):411–21.CrossRef
202.
Dausset C, Bornes S, Miquel S, Kondjoyan N, Angenieux M, Nakusi L, et al. Identification of sulfur components enhancing the anti-candida effect of Lactobacillus rhamnosus Lcr35. Sci Rep. 2020;10(1):17074.PubMedPubMedCentralCrossRef
203.
Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother. 2006;50(4):1463–9.PubMedPubMedCentralCrossRef
204.
Polke M, Leonhardt I, Kurzai O, Jacobsen ID. Farnesol signalling in Candida albicans - more than just communication. Crit Rev Microbiol. 2018;44(2):230–43.PubMedCrossRef
205.
Yapıcı M, Gürsu BY, Dağ İ. In vitro antibiofilm efficacy of farnesol against Candida species. Int Microbiol. 2021;24(2):251–62.PubMedCrossRef
Metadata
Title
The interactions of Candida albicans with gut bacteria: a new strategy to prevent and treat invasive intestinal candidiasis
Authors
Fei Wang
Zetian Wang
Jianguo Tang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2023
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-023-00559-8

Other articles of this Issue 1/2023

Gut Pathogens 1/2023 Go to the issue

Review

Emerging role of bacterial outer membrane vesicle in gastrointestinal tract

Research

Polymorphism of virulence genes and biofilm associated with in vitro induced resistance to clarithromycin in Helicobacter pylori

Review

Gut microbes involvement in gastrointestinal cancers through redox regulation

Research

Comparative genomic analysis of Fusobacterium nucleatum reveals high intra-species diversity and cgmlst marker construction

Research

Antimicrobial growth promoters approved in food-producing animals in South Africa induce shiga toxin-converting bacteriophages from Escherichia coli O157:H7.

Research

CMTM3 protects the gastric epithelial cells from apoptosis and promotes IL-8 by stabilizing NEMO during Helicobacter pylori infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits